Related Experiment Video
Updated: Mar 7, 2026

Circadian Entrainment of Drosophila Melanogaster
Published on: June 3, 2020
Olanzapine-induced early cardiovascular effects are mediated by the biological clock and prevented by melatonin
Francisco Romo-Nava1,2,3, Frederik N Buijs1,4, Marcela Valdés-Tovar5
1Hypothalamic Integration Mechanisms Laboratory, Departamento de Biología Celular y Fisiología, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México (UNAM), México city, DF, México.
Abstract:
Second generation antipsychotics (SGA) are associated with adverse cardiometabolic side effects contributing to premature mortality in patients. While mechanisms mediating these cardiometabolic side effects remain poorly understood, three independent studies recently demonstrated that melatonin was protective against cardiometabolic risk in SGA-treated patients. As one of the main target areas of circulating melatonin in the brain is the suprachiasmatic nucleus (SCN), we hypothesized that the SCN is involved in SGA-induced early cardiovascular effects in Wistar rats. We evaluated the acute effects of olanzapine and melatonin in the biological clock, paraventricular nucleus and autonomic nervous system using immunohistochemistry, invasive cardiovascular measurements, and Western blot. Olanzapine induced c-Fos immunoreactivity in the SCN followed by the paraventricular nucleus and dorsal motor nucleus of the vagus indicating a potent induction of parasympathetic tone. The involvement of a SCN-parasympathetic neuronal pathway after olanzapine administration was further documented using cholera toxin-B retrograde tracing and vasoactive intestinal peptide immunohistochemistry. Olanzapine-induced decrease in blood pressure and heart rate confirmed this. Melatonin abolished olanzapine-induced SCN c-Fos immunoreactivity, including the parasympathetic pathway and cardiovascular effects while brain areas associated with olanzapine beneficial effects including the striatum, ventral tegmental area, and nucleus accumbens remained activated. In the SCN, olanzapine phosphorylated the GSK-3β, a regulator of clock activity, which melatonin prevented. Bilateral lesions of the SCN prevented the effects of olanzapine on parasympathetic activity. Collectively, results demonstrate the SCN as a key region mediating the early effects of olanzapine on cardiovascular function and show melatonin has opposing and potentially protective effects warranting additional investigation.
Insights
Second generation antipsychotics (SGA) cause adverse cardiometabolic effects. Melatonin may protect against these effects by acting on the suprachiasmatic nucleus (SCN), a key brain region involved in cardiovascular regulation.
Area of Science:
- Neuroscience
- Cardiovascular Science
- Pharmacology
Background:
- Second-generation antipsychotics (SGA) are linked to detrimental cardiometabolic side effects, increasing mortality risk.
- The precise mechanisms behind these side effects are not fully understood.
- Recent studies suggest melatonin may offer protection against SGA-induced cardiometabolic risks.
Purpose of the Study:
- To investigate the role of the suprachiasmatic nucleus (SCN) in the early cardiovascular effects of olanzapine, an SGA.
- To explore the potential protective mechanisms of melatonin against olanzapine-induced cardiovascular changes.
Main Methods:
- Immunohistochemistry, invasive cardiovascular measurements, and Western blot were used in Wistar rats.
- Cholera toxin-B retrograde tracing and vasoactive intestinal peptide immunohistochemistry were employed to study neural pathways.
- Bilateral SCN lesions were performed to assess the SCN's role.
Main Results:
- Olanzapine induced parasympathetic tone via a pathway involving the SCN, leading to decreased blood pressure and heart rate.
- Melatonin counteracted olanzapine's effects on the SCN and cardiovascular parameters, while preserving beneficial effects in other brain regions.
- Olanzapine-induced GSK-3β phosphorylation in the SCN was prevented by melatonin.
- SCN lesions abolished olanzapine's effects on parasympathetic activity.
Conclusions:
- The SCN is a critical mediator of olanzapine's early cardiovascular effects.
- Melatonin demonstrates opposing and potentially protective actions against SGA-induced cardiovascular dysfunction.
- These findings highlight the SCN-melatonin axis as a potential therapeutic target for managing SGA side effects.
Related Concept Videos
Management of Insomnia
Chronopharmacokinetics: Circadian Rhythms and Influence on Drug Response
The time of drug administration is an important factor to consider, as it can influence the toxic dose of a drug. For example, a study conducted by Prins et al. in 1997 examined the effects of the timing of...
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Circadian Rhythms and Gene Regulation
Biological Clocks and Seasonal Responses
Sedatives and Hypnotics: Overview
Sedative-hypnotics are categorized into barbiturates, benzodiazepines (BZDs), and non-benzodiazepines or Z-drugs. These drugs work by suppressing central nervous system activity, and this suppression is dose-dependent. Older sedative medications, like barbiturates, follow a linear curve in...

